A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
NCT06307457
·
clinicaltrials.gov ↗
COMPLETED
Status
604
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Palbociclib in combination with AI
Sponsor
Pfizer